

THE LANCET Oncology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Camidge DR, Bang Y-J, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. *Lancet Oncol* 2012; published online Sept 4. [http://dx.doi.org/10.1016/S1470-2045\(12\)70344-3](http://dx.doi.org/10.1016/S1470-2045(12)70344-3).

Supplementary material.**Efficacy and safety of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer: updated results from the molecularly defined cohort of the first-in-man phase I study**

D Ross Camidge MD, Professor Yung-Jue Bang MD, Eunice L Kwak MD, A John Iafrate MD, Professor Marileila Varela-Garcia PhD, Professor Stephen B Fox PhD, Gregory J Riely MD, Benjamin Solomon MBBS, Sai-Hong I Ou MD, Professor Dong-Wan Kim MD, Professor Ravi Salgia MD, Panagiotis Fidias MD, Jeffrey A Engelman MD, Leena Gandhi MD, Pasi A Jänne MD, Daniel B Costa MD, Geoffrey I Shapiro MD, Patricia LoRusso DO, Katherine Ruffner MD, Patricia Stephenson ScD, Yiyun Tang PhD, Keith Wilner PhD, Jeffrey W Clark MD, Alice T Shaw MD

Supplementary Material

Kaplan-Meier plot of progression-free survival in patients who received first-line crizotinib for advanced ALK-positive non-small cell lung cancer (N=24).

